BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 103 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $2,267,000 | -75.0% | 660,000 | -65.3% | 0.62% | -76.5% |
| Q2 2020 | $9,054,000 | +1710.8% | 1,900,000 | +660.0% | 2.62% | +981.0% |
| Q1 2020 | $500,000 | -94.9% | 250,000 | -91.2% | 0.24% | -90.0% |
| Q4 2019 | $9,746,000 | +4677.5% | 2,825,000 | +11200.0% | 2.41% | +2388.7% |
| Q1 2019 | $204,000 | +1.0% | 25,000 | 0.0% | 0.10% | -37.0% |
| Q4 2018 | $202,000 | -95.4% | 25,000 | -97.2% | 0.15% | -81.5% |
| Q4 2017 | $4,419,000 | -15.4% | 900,000 | -9.7% | 0.83% | -10.9% |
| Q3 2017 | $5,221,000 | +456.6% | 996,300 | +490.6% | 0.94% | +255.9% |
| Q2 2017 | $938,000 | -91.0% | 168,685 | -86.5% | 0.26% | -89.4% |
| Q1 2017 | $10,461,000 | +563.3% | 1,245,310 | +400.1% | 2.48% | +323.2% |
| Q4 2016 | $1,577,000 | -49.8% | 249,000 | -65.0% | 0.59% | -50.3% |
| Q3 2016 | $3,141,000 | +1.5% | 712,248 | +162.4% | 1.18% | -34.1% |
| Q3 2015 | $3,094,000 | – | 271,399 | – | 1.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |